Fosun Pharma: Controlled subsidiary drug approved for late-stage solid tumor treatment clinical trials.

Fosun Pharma announced that its controlling subsidiary Fuhong Hanlin has received approval from the National Medical Products Administration to conduct clinical trials for the use of HLX43 in combination with HLX07 and SIRULI monoclonal antibody injection for the treatment of advanced solid tumors. The company plans to conduct Phase II clinical research in China after meeting certain conditions. As of December 2025, the cumulative research and development investment for this treatment plan is approximately 2.66 million yuan. Currently, there are no similar combination therapy treatment plans approved for marketing globally. The drugs involved are still in the clinical trial stage, and there are risks in drug development.